Stoke Therapeutics Inc. (NASDAQ:STOK) shares traded 3.09% higher at $6.33 on Wall Street last session.
In accordance with the data, 10 analysts cover Stoke Therapeutics Inc. (NASDAQ:STOK). The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $35.00 and a low of $12.00, we find $20.00. Given the previous closing price of $6.14, this indicates a potential upside of 225.73 percent. STOK stock price is now -42.76% away from the 50-day moving average and -36.19% away from the 200-day moving average. The market capitalization of the company currently stands at $271.30M.
It has been rated a hold by 2 analysts and a buy by 8. Brokers who have rated the stock have averaged $22.00 as their price target over the next twelve months.
In other news, Ticho Barry, Chief Medical Officer sold 15,000 shares of the company’s stock on Jul 03. The stock was sold for $158,973 at an average price of $10.60. Upon completion of the transaction, the Chief Medical Officer now directly owns 25,895 shares in the company, valued at $0.16 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 21, General Counsel & Corp Sec Allan Jonathan sold 1,948 shares of the business’s stock. A total of $26,252 was realized by selling the stock at an average price of $13.48. Insiders disposed of 105,000 shares of company stock worth roughly $0.66 million over the past 1 year. A total of 5.39% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in STOK stock. A new stake in Stoke Therapeutics Inc. shares was purchased by SIMPLIFY ASSET MANAGEMENT INC. during the first quarter worth $777,000. WOODLINE PARTNERS LP invested $614,000 in shares of STOK during the first quarter. In the first quarter, SQUAREPOINT OPS LLC acquired a new stake in Stoke Therapeutics Inc. valued at approximately $113,000. SUSQUEHANNA INTERNATIONAL GROUP, LLP acquired a new stake in STOK for approximately $98,000. UBS ASSET MANAGEMENT AMERICAS INC purchased a new stake in STOK valued at around $72,000 in the second quarter. In total, there are 163 active investors with 103.84% ownership of the company’s stock.
Stoke Therapeutics Inc. (NASDAQ: STOK) opened at $6.25 on Friday. During the past 12 months, Stoke Therapeutics Inc. has had a low of $5.88 and a high of $22.87. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 8.60, and a quick ratio of 8.60. The fifty day moving average price for STOK is $10.96 and a two-hundred day moving average price translates $9.89 for the stock.
The latest earnings results from Stoke Therapeutics Inc. (NASDAQ: STOK) was released for Mar, 2023. According to the Biotechnology Company, earnings per share came in at -$0.53, beating analysts’ expectations of -$0.7 by 0.17. This compares to -$0.66 EPS in the same period last year. The company reported revenue of $5.15 million for the quarter, compared to $3.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 71.73 percent. For the current quarter, analysts expect STOK to generate $3.44M in revenue.
Stoke Therapeutics Inc.(STOK) Company Profile
Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company is also developing STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. It had entered into a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is based in Bedford, Massachusetts.
